Second consensus on medical treatment of metastatic breast cancer.

Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol (2008) 3.07

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77

Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist (2012) 1.29

Brain metastases free survival differs between breast cancer subtypes. Br J Cancer (2012) 1.11

Targeting invadopodia to block breast cancer metastasis. Oncotarget (2011) 1.10

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol (2008) 1.01

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res (2009) 0.89

Optimal use of taxanes in metastatic breast cancer. Curr Oncol (2009) 0.83

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82

Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol (2011) 0.81

Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer (2009) 0.80

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. Cancer Manag Res (2009) 0.80

Radiofrequency ablation of metastatic lesions from breast cancer. J Ultrasound (2012) 0.78

Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. Breast Care (Basel) (2013) 0.78

The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. Sci Rep (2015) 0.75

Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. Oncologist (2010) 0.75

More options, more considerations: how new treatment options influence clinical decision making. J Thorac Dis (2016) 0.75

Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol (2015) 0.75

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08

Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26

The human beta-interferon gene enhancer is under negative control. Cell (1986) 5.61

Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62

Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2005) 3.24

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07

Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst (1999) 2.99

Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry (1988) 2.96

Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70

Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. Radiology (1997) 2.67

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol (1995) 2.57

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56

Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women. Hum Reprod (1996) 2.52

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50

Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49

Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 2.45

Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19

Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19

Science and government. Navigating the anthropocene: improving Earth system governance. Science (2012) 2.19

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol (2007) 2.18

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol (1997) 2.17

Interleukin-6 is a prognostic factor in multiple myeloma. Blood (1991) 2.16

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14

The value of endoscopic treatment for ureteroceles during the neonatal period. J Urol (1998) 2.13

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res (2000) 2.03

Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med (2008) 2.03

Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax (2013) 2.02

ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer (1998) 1.98

Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer (2003) 1.90

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88

A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res (2000) 1.86

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84

Muscular equivalent of the lower esophageal sphincter. Gastroenterology (1979) 1.83

[Driving tests to determine the influence of alcohol, tranquilizers and hypnotics on driing capability]. Dtsch Med Wochenschr (1969) 1.81

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites. Lancet (2009) 1.81

[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol (1998) 1.80

Predictors of duodenal ulcer healing and relapse. Gastroenterology (1981) 1.78

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78

Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab (1987) 1.78

[Traffic, tranquilizing agents and alcohol]. Dtsch Med Wochenschr (1967) 1.77

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med (2012) 1.76

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics (1996) 1.75

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70

Mucormycoses. Mycoses (2001) 1.70

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67

Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol (2007) 1.67

Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol (1995) 1.66

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer (2001) 1.65

Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol (2012) 1.64

Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol (2001) 1.64

The use of toxic equivalency factors in assessing occupational and environmental health risk associated with exposure to airborne mixtures of polycyclic aromatic hydrocarbons (PAHs). Chemosphere (1996) 1.63

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer (2013) 1.57

Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res (2001) 1.57

Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin (2001) 1.56

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol (2005) 1.56

Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54

'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol (2006) 1.54

[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52

Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast Cancer Res Treat (2010) 1.52

Longitudinal threshold changes in older men with audiometric notches. Hear Res (2000) 1.51

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (2011) 1.51

Lack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest (2003) 1.49